Q4 Biotech Earnings Preview

Here's a cheat sheet for the biotech companies reporting fourth-quarter earnings -- and providing 2014 financial guidance -- this week.

Amgen (AMGN): Jan. 28 after the close

Q4 consensus:
Adjusted EPS: $1.68
Total revenue: $4.82 billion 

Key product sales consensus:
Epogen/Aranesp worldwide: $949 million
Neupogen/Neulasta worldwide: $1.4 billion 
Enbrel worldwide: $1.2 billion 
Kyprolis: $72 million

2014 consensus:
Adjusted EPS: $8.14
Total revenue: $19.58 billion.

Key questions/issues: Biosimilar threat to base business (EPO and filgrastim) sales, evolocumab (PCSK9) clinical/regulatory update.

Biogen Idec (BIIB): Jan. 29 before the open

Q4 consensus:
Adjusted EPS: $2.27
Total revenue: $1.93 billion

Key product sales consensus:
Avonex worldwide: $725 million
Tysabri: $483 million
Tecfidera: $344 million

2014 consensus:
Adjusted EPS: $11.62
Total revenue: $8.35 billion.

Key questions/issues: Discussion of Tecfidera European launch, preparations for hemophilia product launch, pipeline update.

Vertex Pharmaceuticals (VRTX): Jan. 29 after the close

Q4 consensus:
Adjusted EPS: ($0.28)
Total revenue: $234 million

2014 consensus:
Adjusted EPS: ($1.80)
Total revenue: $678.4 million

Key questions/issues: Update on Kalydeco/VX-809 phase III studies and development of fixed-dose pill.

Celgene (CELG): Jan. 30 before the open. [Celgene pre-announced earnings and provdeded guidance on Jan. 13.]

Q4 consensus:
Adjusted EPS: $1.55
Total revenue: $1.713 billion

Key product sales consensus:
Revlimid worldwide: $1.14 billion.
Abraxane: $195 million
Pomalyst: $120 million

2014 consensus:
Adjusted EPS: $7.24
Total revenue: $7.49 billion.

Key questions/issues: Update on Revlimid frontline multiple myeloma regulatory filing and discussion of commercial launch of Otezla (apremilast) in the U.S.

Alexion Pharmaceuticals (ALXN): Jan. 30 before the open

Q4 consensus:
Adjusted EPS: 0.84
Total revenue: $432 million

2014 consensus:
Adjusted EPS: $3.41
Total revenue: $1.95 billion.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

FDA Approves First 'Biosimilar' for Cancer Treatment

Amgen Builds on a Breakout

How I've Prepared for Hurricane Irma -- and a Market Pullback

How I'm Prepared for Irma -- and a Pullback